Last checked at 8 Dec 2021 07:00
Renalytix plc
("Renalytix" or the "Company")
Director/PDMR Dealing
New York, 8 December 2021 - Renalytix (LSE: RENX) announces that it has been advised of the purchase by James McCullough, the Company's Chief Executive Officer, of 950 American Depositary Shares ("ADS") in open market purchases using personal funds, each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), at an aggregate price of $15.04 per ADS.
Following completion of the purchase, James McCullough is interested in 2,742,010 Ordinary Shares representing 3.8% of the current issued share capital of the Company.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore | ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Daniel Adams | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
The information contained in this notification is disclosed in accordance with the requirements of MAR.
1 | Details of the person discharging managerial responsibilities/person closely associated
| ||
a) | Name | James McCullough | |
2 | Reason for the notification
| ||
a) | Position/status | Chief Executive Officer
| |
b) | Initial notification /Amendment
| Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||
a) | Name | Renalytix plc
| |
b) | Legal Entity Identifier | 213800NTOH3FK3WER551
| |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | ADS', each ADS representing two Ordinary Shares of £0.0025 each.
US75973T1016
| |
b) | Nature of the transaction | Purchase of ADS'
| |
c) | Currency
| US Dollar | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
$15.05
| 100 ADS (representing 200 Ordinary Shares)
| ||
$14.86 | 100 ADS (representing 200 Ordinary Shares) | ||
$15.00 | 250 ADS (representing 500 Ordinary Shares) | ||
$15.10 | 500 ADS (representing 1000 Ordinary Shares) | ||
e) | Aggregated information - Aggregated volume - Price - Aggregated total
|
950 ADS (representing 1900 Ordinary Shares) $15.04 $14,291.00 | |
f) | Date of the transaction | 8 December 2021
| |
g) | Place of the transaction | Nasdaq Stock Exchange | |